Rare genetic diseases are a significant burden on society through both uncurbable, often fatal genetic diseases in adults and children as well as a large cost on society through disability and childhood mortality. Existing therapeutic platforms do not address the issue adequately and are often symptomatic. Advanced biotherapeutics are key to addressing the challenges of modern-day healthcare – spiraling cost of long-term chronic illness and lack of cures. 4Bio is a London-based firm focused on private equity and venture capital in Life Sciences. 4Bio invests into advanced therapies addressing high unmet medical and social needs. 4Bio’s investment focus pertains to the largest segments across the new generation of therapeutic platforms including gene therapy, cell therapy, RNA-based therapy, targeted therapy, and microbiome.